KR102671585B1 - 거대환형 광범위 항생제 - Google Patents

거대환형 광범위 항생제 Download PDF

Info

Publication number
KR102671585B1
KR102671585B1 KR1020197026779A KR20197026779A KR102671585B1 KR 102671585 B1 KR102671585 B1 KR 102671585B1 KR 1020197026779 A KR1020197026779 A KR 1020197026779A KR 20197026779 A KR20197026779 A KR 20197026779A KR 102671585 B1 KR102671585 B1 KR 102671585B1
Authority
KR
South Korea
Prior art keywords
alkyl
formula
compound
another embodiment
delete delete
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020197026779A
Other languages
English (en)
Korean (ko)
Other versions
KR20190127720A (ko
Inventor
피터 앤드류 스미스
터커 쿠란 로버츠
로버트 아이. 히구치
프라수나 파라셀리
마이클 에프. 티. 쾨흘러
제이콥 브래들리 슈바르츠
제임스 존 크로포드
쿠옹 큐. 리
에밀리 제이. 하난
휘용 후
용승 첸
지용 유
폴 콜린 마이클 윈십
칼럼 맥클레오드
토비 블렌치
Original Assignee
알큐엑스 파마슈티컬스, 인크.
제넨테크, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 알큐엑스 파마슈티컬스, 인크., 제넨테크, 인크. filed Critical 알큐엑스 파마슈티컬스, 인크.
Publication of KR20190127720A publication Critical patent/KR20190127720A/ko
Application granted granted Critical
Publication of KR102671585B1 publication Critical patent/KR102671585B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1019—Tetrapeptides with the first amino acid being basic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D245/00—Heterocyclic compounds containing rings of more than seven members having two nitrogen atoms as the only ring hetero atoms
    • C07D245/04—Heterocyclic compounds containing rings of more than seven members having two nitrogen atoms as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0821—Tripeptides with the first amino acid being heterocyclic, e.g. His, Pro, Trp
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1016—Tetrapeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
KR1020197026779A 2017-02-15 2018-02-22 거대환형 광범위 항생제 Active KR102671585B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CNPCT/CN2017/073575 2017-02-15
CNPCT/CN2017/073575 2017-02-15
CNPCT/CN2017/085075 2017-05-19
CNPCT/CN2017/085075 2017-05-19
PCT/CN2018/076957 WO2018149419A1 (en) 2017-02-15 2018-02-22 Macrocyclic broad spectrum antibiotics

Publications (2)

Publication Number Publication Date
KR20190127720A KR20190127720A (ko) 2019-11-13
KR102671585B1 true KR102671585B1 (ko) 2024-06-04

Family

ID=63169158

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020197026779A Active KR102671585B1 (ko) 2017-02-15 2018-02-22 거대환형 광범위 항생제

Country Status (23)

Country Link
US (2) US20210198316A9 (https=)
EP (2) EP4371982A3 (https=)
JP (2) JP7134177B2 (https=)
KR (1) KR102671585B1 (https=)
CN (1) CN110520413B (https=)
AU (2) AU2018222093B2 (https=)
BR (1) BR112019017003A2 (https=)
CA (1) CA3053205A1 (https=)
CL (1) CL2019002305A1 (https=)
CO (1) CO2019010001A2 (https=)
CR (2) CR20190428A (https=)
ES (1) ES2979245T3 (https=)
IL (1) IL268483B2 (https=)
MA (1) MA47514A (https=)
MX (2) MX2019009752A (https=)
MY (1) MY199461A (https=)
NZ (1) NZ779474A (https=)
PE (2) PE20191618A1 (https=)
PH (1) PH12019501904A1 (https=)
SG (2) SG11201907448RA (https=)
UA (1) UA126027C2 (https=)
WO (1) WO2018149419A1 (https=)
ZA (1) ZA201905371B (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11072635B2 (en) 2015-11-20 2021-07-27 Rqx Pharmaceuticals, Inc. Macrocyclic broad spectrum antibiotics
CN109983012B (zh) 2016-09-16 2023-12-01 莱特豪斯制药公司 赖氨酸牙龈蛋白酶的酮抑制剂
ES2961566T3 (es) * 2019-05-28 2024-03-12 Hoffmann La Roche Antibióticos macrocíclicos de amplio espectro
CN112480007B (zh) * 2020-12-08 2022-11-18 宿迁市科莱博生物化学有限公司 一种1，3-二甲基-1h-吡唑-4-羧酸的合成方法
CN116284026B (zh) * 2023-03-16 2024-05-14 天津师范大学 一种水溶性阳离子分子笼及其合成方法与应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012166665A2 (en) 2011-05-27 2012-12-06 Rqx Pharmaceuticals, Inc. Broad spectrum antibiotics
WO2013138187A1 (en) 2012-03-14 2013-09-19 The Scripps Research Institute Broad spectrum antibiotic arylomycin analogs
WO2015179441A2 (en) 2014-05-20 2015-11-26 Rqx Pharmaceuticals, Inc. Macrocyclic broad spectrum antibiotics

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2012010381A (es) * 2010-03-09 2012-11-23 Merck Canada Inc Lipoglicopeptidos en puente que potencian la actividad de antibacterianos de beta-lactama.
US9187524B2 (en) * 2010-09-15 2015-11-17 The Scripps Research Institute Broad spectrum antibiotic arylomycin analogs
EP2913854B1 (en) * 2012-10-23 2020-05-27 Fuji Electric Co., Ltd. Semiconductor device and method for manufacturing same
CN103788176A (zh) * 2012-10-31 2014-05-14 上海来益生物药物研究开发中心有限责任公司 一种arylomycin类化合物及其制备方法和应用
EA201590871A1 (ru) * 2012-11-21 2015-11-30 АрКьюЭкс ФАРМАСЪЮТИКЛС, ИНК. Макроциклические антибиотики широкого спектра действия
US20190067498A1 (en) * 2017-08-28 2019-02-28 Meng Tao Light-induced aluminum plating on silicon for solar cell metallization
TWI725075B (zh) * 2015-11-20 2021-04-21 美商Ｒｑｘ製藥公司 巨環廣效抗生素
US11072635B2 (en) 2015-11-20 2021-07-27 Rqx Pharmaceuticals, Inc. Macrocyclic broad spectrum antibiotics
CN117777229A (zh) 2017-03-27 2024-03-29 豪夫迈·罗氏有限公司 用于制备阿龙霉素环类似物的方法

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012166665A2 (en) 2011-05-27 2012-12-06 Rqx Pharmaceuticals, Inc. Broad spectrum antibiotics
WO2013138187A1 (en) 2012-03-14 2013-09-19 The Scripps Research Institute Broad spectrum antibiotic arylomycin analogs
WO2015179441A2 (en) 2014-05-20 2015-11-26 Rqx Pharmaceuticals, Inc. Macrocyclic broad spectrum antibiotics

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Jeremy Dufour et al. Chemistry A European Journal. 2010, Vol. 16, pp. 10523-10534
Tucker C. Roberts et al. Journal of Medicinal Chemistry. 2011, Vol. 54, pp. 4954-4963

Also Published As

Publication number Publication date
IL268483A (en) 2019-09-26
EP3583096A1 (en) 2019-12-25
EP3583096B1 (en) 2024-03-27
CO2019010001A2 (es) 2020-04-01
PE20191618A1 (es) 2019-11-05
CA3053205A1 (en) 2018-08-23
AU2022201724A1 (en) 2022-04-07
CN110520413A (zh) 2019-11-29
CL2019002305A1 (es) 2020-04-13
PH12019501904A1 (en) 2019-10-21
US20210198316A9 (en) 2021-07-01
KR20190127720A (ko) 2019-11-13
SG11201907448RA (en) 2019-09-27
IL268483B2 (en) 2024-02-01
AU2022201724B2 (en) 2024-02-29
SG10202108876TA (en) 2021-09-29
US20200024309A1 (en) 2020-01-23
JP2020507564A (ja) 2020-03-12
AU2018222093B2 (en) 2022-03-31
CN110520413B (zh) 2023-02-17
RU2019126728A3 (https=) 2021-09-15
ZA201905371B (en) 2025-01-29
BR112019017003A2 (pt) 2020-04-14
MA47514A (fr) 2019-12-25
UA126027C2 (uk) 2022-08-03
AU2018222093A1 (en) 2019-08-29
PE20242298A1 (es) 2024-12-11
US20230133667A1 (en) 2023-05-04
MX2022014485A (es) 2022-12-13
AU2022201724B9 (en) 2024-03-21
MY199461A (en) 2023-10-30
NZ779474A (en) 2025-12-19
EP3583096A4 (en) 2021-01-06
JP7134177B2 (ja) 2022-09-09
EP4371982A2 (en) 2024-05-22
RU2019126728A (ru) 2021-03-16
JP2022180390A (ja) 2022-12-06
WO2018149419A1 (en) 2018-08-23
MX2019009752A (es) 2019-11-11
EP4371982A3 (en) 2024-08-21
JP7461425B2 (ja) 2024-04-03
CR20190428A (es) 2020-02-13
CR20210144A (es) 2021-05-13
NZ756220A (en) 2021-09-24
EP3583096C0 (en) 2024-03-27
IL268483B1 (en) 2023-10-01
ES2979245T3 (es) 2024-09-25

Similar Documents

Publication Publication Date Title
JP7148652B2 (ja) 大環状広域スペクトル抗生物質
JP2022046563A (ja) ベータラクタマーゼ阻害剤化合物
JP7461425B2 (ja) 大環状広域抗生物質
US20230133817A1 (en) Macrocyclic broad spectrum antibiotics
CN109219596B (zh) 大环广谱抗生素
KR20160044512A (ko) 선형 펩티드 항생제
RU2779477C2 (ru) Макроциклические антибиотики широкого спектра
NZ756220B2 (en) Macrocyclic broad spectrum antibiotics
BR122021010304B1 (pt) Antibióticos macrocíclicos de amplo espectro
HK40012941B (en) Macrocyclic broad spectrum antibiotics
HK40012941A (en) Macrocyclic broad spectrum antibiotics
HK40000284A (en) Macrocyclic broad spectrum antibiotics
HK40002868A (en) Macrocyclic broad spectrum antibiotics

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20190911

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
AMND Amendment
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20210222

Comment text: Request for Examination of Application

AMND Amendment
E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20230428

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20231127

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20230428

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

X091 Application refused [patent]
AMND Amendment
PX0901 Re-examination

Patent event code: PX09011S01I

Patent event date: 20231127

Comment text: Decision to Refuse Application

Patent event code: PX09012R01I

Patent event date: 20230628

Comment text: Amendment to Specification, etc.

Patent event code: PX09012R01I

Patent event date: 20210511

Comment text: Amendment to Specification, etc.

Patent event code: PX09012R01I

Patent event date: 20210222

Comment text: Amendment to Specification, etc.

PX0701 Decision of registration after re-examination

Patent event date: 20240423

Comment text: Decision to Grant Registration

Patent event code: PX07013S01D

Patent event date: 20240325

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

Patent event date: 20231127

Comment text: Decision to Refuse Application

Patent event code: PX07011S01I

Patent event date: 20230628

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

Patent event date: 20210511

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

Patent event date: 20210222

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

X701 Decision to grant (after re-examination)
GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20240529

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20240529

End annual number: 3

Start annual number: 1

PG1601 Publication of registration